Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 28;5(5):e000911. doi: 10.1136/esmoopen-2020-000911

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Consolidated Standards of Reporting Trials diagram of HERACLES-B trial. Between August 2012 and March 2018, 1536 patients with KRAS exon 2 and BRAF wild type (WT) (from 15 March 2016 exons 2, 3, 4 KRAS and NRAS and BRAF WT) were screened by immunohistochemistry (IHC) and in situ hybridisation (ISH) as per HERACLES criteria. Ninety patients (5.9%) had a HER2+ tumour. HERACLES cohort A comprised overall 35 patients (27 original cohort plus 8 expansion cohort), of whom 32 were evaluable for response.8 Enrolment in cohort B (HERACLES B trial) started in August 2016, data were collected until March 2019 and final analysis and centralised radiological revision were completed by 30 July 2019. One patient signed consent but developed rapid disease progression and was locally indicated as not evaluable for efficacy. The patients was duly substituted as per protocol. However, the centralised revision of the treatment history subsequently revealed instead that patient was fully evaluable for both safety and efficacy as for protocol since two full cycles of treatment were delivered. For this reason, all analyses have been performed on 31 rather than 30 patients as originally intended. *From 15 March 2016 RAS WT (KRAS, NRAS exon 2, 3, 4).